Lepu Biopharma Co., Ltd. (HKG:2157)
2.510
-0.065 (-2.52%)
Nov 19, 2026, 11:45 AM HKT
Lepu Biopharma Revenue
Lepu Biopharma had revenue of 522.41M CNY in the half year ending June 30, 2026, with 291.96% growth. This brings the company's total for the last twelve months to 991.34M, up 41.53% year-over-year. In the year 2025, Lepu Biopharma had annual revenue of 934.87M with 154.18% growth. That makes Lepu Biopharma the 19,864th largest company in the world by revenue and 1,155th in Hong Kong.
Revenue (ttm)
991.34M CNY
Revenue Growth
+41.53%
P/S Ratio
4.06
Revenue / Employee
1.53M CNY
Employees
646
Market Cap
4.53B HKD
Revenue by Geography
- People's Republic of China (PRC) 571.08M 61.1%
- Overseas 363.79M 38.9%
Fiscal year ended Dec 31, 2025 See the full Lepu Biopharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 934.87M | 567.08M | 154.18% |
| Dec 31, 2024 | 367.79M | 142.44M | 63.21% |
| Dec 31, 2023 | 225.35M | 209.78M | 1,347.16% |
| Dec 31, 2022 | 15.57M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.52B |
| Frontage Holdings | 2.18B |
| Ocumension Therapeutics | 1.08B |
| Alphamab Oncology | 598.06M |
| Mirxes Holding Company | 166.32M |
| CARsgen Therapeutics Holdings | 157.72M |
| Abbisko Medicine | 112.29M |
| Shanghai Bao Pharmaceuticals | 19.67M |
Lepu Biopharma News
- 3 months ago - Lepu Biopharma Reports Revenue Growth As Oncology Pipeline Advances - Nasdaq
- 3 months ago - AstraZeneca's Sone-Ve Improves Survival In Gastric Cancer Trial - Nasdaq